

**CERTIFICATE ON
STATUS REPORT ON UTILIZATION
OF
PROCEEDS FROM PUBLIC OFFERING
OF
Navana Pharmaceuticals PLC.**

For the quarter ended September 30, 2025



PrimeGlobal

*An Association of
Independent Accounting Firms*



Independent Auditors' Report
To Navana Pharmaceuticals PLC. and Bangladesh Securities and Exchange Commission
Report on the Audit of IPO (Initial Public Offering) Proceeds Utilization Statement

Opinion

We have audited the annexed IPO (Initial Public Offering) proceeds utilization statement of Navana Pharmaceuticals PLC for the quarter ended September 30, 2025 ("utilization statement").

In our Opinion, the IPO (Initial Public Offering) proceeds utilization statement of Navana Pharmaceuticals PLC ("the Company") for the quarter ended September 30, 2025 is prepared, in all material respects, in accordance with Bangladesh Securities and Exchange Commission (BSEC) Rules 2022, conditions laid down in the clause 3 & 4 of PART-D of the consent letter BSEC/CI/IPO-323/2022/853 Dated June 19, 2022.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the IPO (Initial Public Offering) proceeds utilization statement section of our report. We are independent of the Company in accordance with the ethical requirement that are relevant to our audit of the utilization statement in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Matters – Basis of Preparation , Restriction on Distribution and Compliance with Local Laws

The utilization statement is prepared to assist the Company to meet the requirements of Bangladesh Securities and Exchange Commission ("BSEC"). As a result, the utilization statement may not be suitable for another purpose. Our report is intended solely for the Company and the BSEC and should not be distributed to parties other than the Company or the BSEC.

Responsibilities of Management and Those Charged with Governance for the IPO (Initial Public Offering) Proceeds Utilization Statement

Management is responsible for the preparation and fair presentation of the IPO (Initial Public Offering) proceeds utilization statement prepared in accordance with Bangladesh Securities and Exchange Commission (BSEC) Rules 1987, condition laid down in the clause 3 & 4 of PART-D of the consent letter BSEC/CI/IPO-323/2022/853 dated June 19, 2022 and with other applicable laws and regulations.

In preparing the utilization statement, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the IPO (Initial Public Offering) Proceeds Utilization Statement

Our objectives are to obtain reasonable assurance about whether the IPO (Initial Public Offering) proceeds utilization statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this utilization statement.


Cont.....

As part of an audit in accordance with ISAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- a) Identify and assess the risks of material misstatement of the IPO (Initial Public Offering) proceeds utilization statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- d) Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the utilization statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Date: 15 October, 2025
Place: Dhaka.


Shafi Uddin Ahmed, FCA
Partner
FAMES & R
Chartered Accountants



IPO Proceeds Utilization Statement

For the quarter ended September 30, 2025

Name of the Company :Navana Pharmaceuticals PLC.

Capital Raised through IPO :BDT 750,000,000

(Book building method)

Proceeds Receiving Date :Eligible Investors & Employees on July 19, 2022 (BDT 19,61,50,200) and General Public on October 04, 2022 (BDT 55,38,49,800)

Subscription Closing Date :9/19/2022

Last date of full utilization fund as per prospectus :10/3/2025

Sl. No.	Name of the projects	Estimated cost of project implementation (in BDT)	Estimated time for completion	Fund utilization during the period from October 01, 2022 to June 30, 2024		Fund utilization during the period from July 01, 2024 to March 31, 2024		Fund utilization during the period from April 01, 2025 to June 30, 2025		Fund utilization during the period from July 01, 2025 to September 30, 2025		Variance	Unutilized	Remarks
				BDT	%	BDT	%	BDT	%	BDT	%			
1	Construction of New Generic Production Unit	131,185,000	Within 36 month after receiving IPO proceeds	50,000,000	38.11%	35,317,331	26.92%	45,819,285	34.93%	-	0.00%	48,383	0.04%	-
2	Modernaization and expansion of General liquid facility with dispensing area	46,815,000	Within 36 month after receiving IPO proceeds	46,320,133	98.94%	-	0.00%	478,499	1.02%	-	0.00%	16,368	0.03%	-
3	Modernaization and expansion of Animal health facility	54,400,000	Within 36 month after receiving IPO proceeds	15,965,737	29.35%	15,020,000	27.61%	1,000,000	1.84%	22,341,596	41.07%	72,667	0.13%	-
4	Construction of new utility and engineering building	97,300,000	Within 36 month after receiving IPO proceeds	97,209,255	99.91%	90,745	0.09%	-	0.00%	-	0.00%	0	0.00%	-
5	Refurbishment of cephalosporin unit	178,500,000	Within 36 month after receiving IPO proceeds	178,497,760	100.00%	-	0.00%	-	0.00%	-	0.00%	2,240	0.00%	-



6	Partial loan repayment	211,800,000	Within 06 month after receiving IPO proceeds	211,800,000	100.00%	-	0.00%	-	0.00%	-	0.00%	-	0.00%	-
7	IPO expenses	30,000,000	N/A	29,969,243	99.90%	-	0.00%	-	0.00%	-	0.00%	30,757	0.10%	-
8	Bank Charges and levies	-	N/A	118,249	-	50,660	-	445.00	-	160.00		(169,515)	0.00%	-
Total IPO Proceeds		750,000,000		629,880,377	83.98%	50,478,736	6.73%	47,298,229	6.31%	22,341,756	2.98%	900.10	0.00%	-

Footnotes:


- Excise Duty of BDT 150,000, bank charge of BDT 2,000, certificate charge of BDT 300, VAT of BDT 2,284.24, RTGS charge of BDT 1,430.76, cheque issuance charge of BDT 12,000 and accounts maintenance charge of BDT 1,500 had been debited from IPO Bank account;
 - The utilization statement was approved and authorized for issue by the Board of Directors on 15 October 2025 and signed for and on behalf of the Board.
 - Our IPO proceeds were Tk. 75 crore, and up to September 30, 2025, we have utilized 100% of the funds except for Tk. 900.
- * we may use Bank Charges and levies instead of others expenses.


Finance Director & CFO
Navana Pharmaceuticals PLC.


Company Secretary
Navana Pharmaceuticals PLC.


Director
Navana Pharmaceuticals PLC.


Acting Managing Director
Navana Pharmaceuticals PLC.


Shafi Uddin Ahmed, FCA
Partner
FAMES & R
Chartered Accountants

Date: 15 October, 2025
Place: Dhaka.

